Cardiovascular therapies and risk for development of diabetes.
The prevalence of diabetes is increasing, and patients with diabetes are at increased risk of adverse cardiovascular outcomes. Recently, the results from 11 large randomized clinical trials have suggested a difference in the emergence of new diabetes according to cardiovascular medication use. Treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium antagonists yielded a lower incidence of diabetes development than beta-blockers and diuretics. Physicians should consider this possible diabetes consequence when prescribing long-term beta-blockers and diuretics, particularly in patients at high risk of developing diabetes.
Pepine
Carl J
CJ
Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida 32610-0277, USA. pepincj@medicine.ufl.edu
Cooper-Dehoff
Rhonda M
RM
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D002317:Cardiovascular Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000517:prevention & control*; D004232:Diuretics / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D004232:Diuretics